ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2020
Hematologic Markers and Prostate Cancer Risk: A Prospective Analysis in UK Biobank.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- The low-grade Inflammation Score (INFLA-Score) as a predictor of overall survival in prostate cancer: a UK biobank cohort study.BMC urology · 2026Article
- Leveraging [Clinical and translational science · 2026Article
- Hematological parameters as predictors of prostate cancer: A study based on multivariable and bidirectional Mendelian randomization.Medicine · 2025Article
- The immune landscape of systemic inflammation in prostate cancer.Cancer biology & medicine · 2025Review
- Red cell indices as predictors of cancer risk: findings from a large prospective cohort study.BMC cancer · 2025Article
- The association between white blood cell count and relative risk of non-small cell lung cancer.Discover oncology · 2025Article
- Comprehensive interaction modeling with machine learning improves prediction of disease risk in the UK Biobank.Nature communications · 2025Article
- Diagnostic Significance of Serum Ferritin and Hepcidin as Complementary Biomarkers for Prostate Disease: A Prospective Case-Control Study in a Mission Hospital, Ghana.Health science reports · 2025Article
- Severe obesity, high inflammation, insulin resistance with risks of all-cause mortality and all-site cancers, and potential modification by healthy lifestyles.Scientific reports · 2025Article
- Development and validation of a prostate cancer risk prediction model for the elevated PSA population.Frontiers in oncology · 2025Article
- Deciphering the causal landscape: genetic insights into sporadic vestibular schwannoma risk factors through Mendelian Randomization.Discover oncology · 2024Article
- Allometric fat mass index and alanine aminotransferase attenuate the associations of platelet parameters with lung cancer risk.Scientific reports · 2024Article
- An Exploration of Shared Risk Factors for Coronary Artery Disease and Cancer from 109 Traits: The Evidence from Two-Sample Mendelian Randomization Studies.Reviews in cardiovascular medicine · 2024Article
- Mendelian randomization evidence based on European ancestry for the causal effects of leukocyte telomere length on prostate cancer.Human genomics · 2024Article
- Biological basis of extensive pleiotropy between blood traits and cancer risk.Genome medicine · 2024Article
- Causal association between peripheral immune cells and IgA nephropathy: a Mendelian randomization study.Frontiers in immunology · 2024Article
- Associations of HALP score with serum prostate-specific antigen and mortality in middle-aged and elderly individuals without prostate cancer.Frontiers in oncology · 2024Article
- Circulating white blood cell traits and colorectal cancer risk: A Mendelian randomisation study.International journal of cancer · 2024Article
- Inflammation in Prostate Cancer: Exploring the Promising Role of Phenolic Compounds as an Innovative Therapeutic Approach.Biomedicines · 2023Review
- Exploring regression dilution bias using repeat measurements of 2858 variables in ≤49 000 UK Biobank participants.International journal of epidemiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundRisk factors for prostate cancer are not well understood. Red blood cell, platelet, and white blood cell indices may be markers of a range of exposures that might be related to prostate cancer risk. Therefore, we examined the associations of hematologic parameters with prostate cancer risk.
methodsComplete blood count data from 209,686 male UK Biobank participants who were free from cancer at study baseline were analyzed. Participants were followed up via data linkage. After a mean follow-up of 6.8 years, 5,723 men were diagnosed with prostate cancer and 323 men died from prostate cancer. Multivariable-adjusted Cox regression was used to estimate adjusted HRs and 95% confidence intervals (CI) for prostate cancer incidence and mortality by hematologic parameters, and corrected for regression dilution bias.
resultsHigher red blood cell (HR per 1 SD increase = 1.09, 95% CI, 1.05-1.13) and platelet counts (HR = 1.07, 1.04-1.11) were associated with an increased risk of prostate cancer. Higher mean corpuscular volume (HR = 0.90, 0.87-0.93), mean corpuscular hemoglobin (HR = 0.90, 0.87-0.93), mean corpuscular hemoglobin concentration (HR = 0.87, 0.77-0.97), and mean sphered cell volume (HR = 0.91, 0.87-0.94) were associated with a lower prostate cancer risk. Higher white blood cell (HR = 1.14, 1.05-1.24) and neutrophil count (HR = 1.27, 1.09-1.48) were associated with prostate cancer mortality.
conclusionsThese associations of blood indices of prostate cancer risk and mortality may implicate shared common causes, including testosterone, nutrition, and inflammation/infection among several others in prostate cancer development and/or progression. IMPACT: These associations provide insights into prostate cancer development and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.